---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086103"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:29:25.001515+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY

## Summary
- Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.
- Non-GAAP adjusted diluted EPS $1.12 (down 15% YoY); GAAP diluted EPS $0.75 (down 21%).
- Women's Health +3%, Biosimilars +22% driven by Hadlima launch; Established Brands -1% ex-FX.
- FY2024 revenue guidance narrowed to $6.25-6.45B; Adjusted EBITDA margin reaffirmed 31-33%.

## SEC filing metadata
- accession: 0001104659-24-086103
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465924086103/0001104659-24-086103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465924086103/tm2420930d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086103
- JSON: https://secwatch.observer/filing/0001104659-24-086103.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.